-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FqZocAjg0+RCzjkBA8ln2Zm+J/A5hIxLS6WKs40vCApEe8r3zSim+A7eb2dt//MU 0kvFR90FpK8C/o1Pp09CEQ== 0001036050-99-001945.txt : 19990924 0001036050-99-001945.hdr.sgml : 19990924 ACCESSION NUMBER: 0001036050-99-001945 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19990913 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19990923 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE CENTRAL INDEX KEY: 0000094784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870277826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-06533 FILM NUMBER: 99715572 BUSINESS ADDRESS: STREET 1: 137 NEWBURY STREET STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6174250200 MAIL ADDRESS: STREET 1: 137 NEWBURY STREET STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE DATE OF NAME CHANGE: 19790521 8-K 1 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) September 13, 1999 ---------------------- BOSTON LIFE SCIENCES, INC. -------------------------- (Exact name of registrant as specified in its charter)
Delaware 0-6533 87-0277826 - --------------------- ------------------ -------------------- (State or other jurisdiction of (Commission (I.R.S. Employer Identification No.) incorporation or organization) File No.)
137 Newbury Street 8/th/ Floor Boston, Massachusetts 02116 - ------------------------------------------ ---------------------- (Address of principal executive offices) Zip Code Registrant's telephone number, including area code (617) 425-0200 ----------------- Item 5. Other Events. ------------- On September 13, 1999, the Company announced that it had entered into a development and licensing agreement with Pfizer, Inc. to further develop a major sector of the Company's C-Maf technology. C-Maf is an important transcriptional regulator of IL-4 production and is the only known tissue-specific transcription factor that is capable of physiologically transforming Th1 cells into Th2 cells. The Company believes that C-Maf inhibitors could potentially be used to treat a broad spectrum of allergies and asthma. Under the terms of the agreement (which includes a transfer of the technology), Pfizer will screen its small molecule collection for potential inhibitors of C-Maf, with the goal of developing a small molecule therapeutic drug for the treatment of a wide range of allergies and asthma. The Company will receive an undisclosed initial payment and royalties on eventual sales of any product potentially derived from the development effort. The Company stated that it will continue to independently develop C-Maf as gene therapy for the treatment of severe autoimmune disease such as Type 1 Diabetes and Multiple Sclerosis. The foregoing contains forward-looking statements with regard to product development intentions on the part of BLSI and its licensees and assumptions on the clinical efficacy and commercial viability of products and/or technologies, which may not be realized due to the uncertainties inherent in the research and development process, regulatory approval process and the determination of licensees with respect to their continued development of technology licensed from BLSI. Item 7. Exhibits. --------- The following Exhibits are filed as part of this report on Form 8-K: 99.1 Press Release, dated September 13, 1999. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto authorized. BOSTON LIFE SCIENCES, INC. Dated: September 22, 1999 By: /s/Joseph Hernon --------------------------- Joseph Hernon Chief Financial Officer 2 BOSTON LIFE SCIENCES, INC. CURRENT REPORT ON FORM 8-K EXHIBIT INDEX Exhibit No. Pages ----------- ----- 99.1 Press Release, dated September 13, 1999 4 - 5 3 EX-99.1 2 PRESS RELEASE, DATED SEPTEMBER 13, 1999 Exhibit 99.1 FOR IMMEDIATE RELEASE BOSTON LIFE SCIENCES SIGNS LICENSING AGREEMENT WITH PFIZER FOR ALLERGY AND ASTHMA September 13, 1999, Boston, MA--Boston Life Sciences, Inc. (NASDAQ: BLSI) announced that the Company had entered into a development and licensing agreement with Pfizer, Inc. to further develop a major sector of BLSI's C-Maf technology. "Since the discovery by Professor Laurie Glimcher of C-Maf and its publication in Cell (vol. 85; 973-983; 1996), we have been collaborating with Prof. Glimcher to develop a high-throughput screen that can be used to identify inhibitors of C-Maf. C-Maf is an important transcriptional regulator of IL-4 production and is the only known tissue-specific transcription factor that is capable of physiologically transforming Th1 cells into Th2 cells. Conversely, as elucidated by Prof. Glimcher, inhibition of C-Maf transforms Th2 cells into Th1 cells. Since Th2 cells are essential to the triggering of allergies and asthma and their debilitating symptomatology, C-Maf inhibitors potentially could be used to treat a broad spectrum of these conditions. We are delighted that Pfizer intends to utilize this technology to identify potential small molecule inhibitors of C-Maf and thus embark on a new approach to the treatment of allergies and asthma," stated Dr. Marc Lanser, Chief Scientific Officer of BLSI. Under the terms of the agreement (which includes a transfer of the technology to Pfizer), Pfizer will screen its small molecule collection for potential inhibitors of C-Maf, with the goal of developing a small molecule therapeutic drug for the treatment of a wide range of allergies and asthma. BLSI will receive an undisclosed initial payment and royalties on eventual sales of any product potentially derived from the development effort. "BLSI will also continue to independently further develop C-Maf as gene therapy for the treatment of severe autoimmune disease such as Type 1 Diabetes and Multiple Sclerosis," added Dr. Lanser. "Given the extremely important transcription factor and gene vector technologies discovered by Prof. Glimcher delineating the key role that Th1 and Th2 cells play in the development of autoimmune disease and allergies, we believe that several collaborative relationships can eventually radiate from the core of her work, which is centered on controlling the production of critical cytokines (immune system regulators) at the genetic level. We hope to co-develop two gene therapy products, and at least four small molecule inhibitors for the treatment of autoimmune disease, allergies, cancer and AIDS based on this work," stated Dr. Lanser. --more-- 4 About Boston Life Sciences, Inc. BLSI is developing novel treatments for cancer, autoimmune disease, and central nervous system disorders. In addition to C-Maf, products awaiting FDA review, in clinical trials or in preclinical development by BLSI include Therafectin(R) for the treatment of Rheumatoid Arthritis; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease and Attention Deficit Hyperactivity Disorder (ADHD); Troponin I, an anti-angiogenic factor for the treatment of solid tumor metastases; AF-1 for the potential treatment of stroke and spinal cord injury; and fusion toxins for the treatment of adenocarcinomas, allergies, and multiple sclerosis. The foregoing contains forward-looking statements with regard to product development intentions on the part of BLSI and its licensees and assumptions on the clinical efficacy and commercial viability of products and/or technologies, which may not be realized due to the uncertainties inherent in the research and development process, regulatory approval process and the determination of licensees with respect to their continued development of technology licensed from BLSI. For further information Media Contact Analyst Contact Boston Life Sciences, Inc. Jim Weinrebe Neil Berkman Marc E. Lanser, M.D. Lauren Arnold Neil Berkman Associates Chief Scientific Officer Schwartz Communications 310.277.5162 617.425.0200 781.684.0770 www.bostonlifesciences.com 781.684.0771 5 -----END PRIVACY-ENHANCED MESSAGE-----